Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Gartner, C. Martin, P. Vallejos, A. Moreno, I. de Mir, A. Torrent, M. Razquin (Barcelona, Madrid, Spain). Nebulised antibiotics with the I-neb adaptive aerosol delivery (AAD) system: Impact on adherence in cystic fibrosis (CF) patients. Eur Respir J 2012; 40: Suppl. 56, 1119

Member's Comments

No comment yet.

Related content which might interest you: The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Self-perceived verses electronic monitoring of adherence to nebulised treatment in children with cystic fibrosis - does the use of telehealth system improve nebulisation adherence? Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Ventilation inhomogeneity (VI) and spirometry in response to intravenous antibiotics (IVab) in cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Precise dosing of five drugs commonly used by patients with cystic fibrosis using an adaptive aerosol delivery system Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 The prevalence and characteristics of intravenous (IV) antibiotics allergy in adult patient with cystic fibrosis (CF) Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Use of an electronic monitoring system to generate objective information on patients’ adherence to taking treatments of a novel inhaled tobramycin solution Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003 Change in lung clearance index (LCI) following intravenous antibiotic intervention in children with CF Source: Annual Congress 2008 - Respiratory physiology in health and disease Year: 2008 High frequency chest wall oscillation (HFCWO) in the treatment of acute pulmonary exacerbation in adult cystic fibrosis (CF) patients Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Use of a new feedback tool to optimize inhaled aerosol therapy in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 261s Year: 2006 Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis) Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018 Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients’ attitudes Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Combination of inhaled corticosteroids and long acting beta two agonists improve lung clearance index (LCI) in preschoolers with cystic fibrosis Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge Year: 2011